WO2020190703A1 - Méthodes pour le traitement de plaies - Google Patents

Méthodes pour le traitement de plaies Download PDF

Info

Publication number
WO2020190703A1
WO2020190703A1 PCT/US2020/022596 US2020022596W WO2020190703A1 WO 2020190703 A1 WO2020190703 A1 WO 2020190703A1 US 2020022596 W US2020022596 W US 2020022596W WO 2020190703 A1 WO2020190703 A1 WO 2020190703A1
Authority
WO
WIPO (PCT)
Prior art keywords
wound
pterostilbene
nicotinamide riboside
composition
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2020/022596
Other languages
English (en)
Inventor
Eric MARCOTULLI
Dan ALMINANA
Mark Morris
Ryan DELLINGER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elysium Health Inc
Original Assignee
Elysium Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elysium Health Inc filed Critical Elysium Health Inc
Publication of WO2020190703A1 publication Critical patent/WO2020190703A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom

Definitions

  • the present application provides methods for treating wounds by administering a combination of nicotinamide riboside and pterostilbene.
  • the compositions can be administered orally or as a topical formulation.
  • fibrin synthesis and accumulation takes place. This causes an increase in wound tensile strength and stimulation of fibroblast proliferation and growth.
  • Fibroblasts secrete collagen, a fibrous protein as part of connective tissue. Collagen deposition begins from the fifth day and results in rapid gain in tensile strength of the wound.
  • the third phase is the maturational process. Tensile strength continues to increase from the cross-linking of collagen fibers. Deposition of fibrous connective tissue causes scar formation. [0007] In all phases, compositions that can aid or speed the wound healing process are highly desired.
  • the present invention fulfills these needs by providing compositions and methods for treatment of wounds.
  • a method for treating a wound comprising administering a composition comprising a therapeutically effective amount of nicotinamide riboside and a therapeutically effective amount of pterostilbene to a patient having the wound.
  • methods for treating an open wound comprising administering a composition consisting essentially of a therapeutically effective amount of nicotinamide riboside and a therapeutically effective amount of pterostilbene to a patient having the open wound.
  • a method for treating a closed wound comprising administering a composition consisting essentially of a therapeutically effective amount of nicotinamide riboside and a therapeutically effective amount of pterostilbene to a patient having the closed wound.
  • FIGs. 1A-1C show the combination of NR and PT effect on UVB-induced ear swelling at 24, 48, 72 and 96 hours.
  • FIG. 2 shows the effect of NR, PT and NR+PT on the formation of pyrimidine- pyrimidone (6-4) (6,4 PPD) photo-products. ** P ⁇ 0.01. DETAILED DESCRIPTION OF THE INVENTION
  • wounds are caused by trauma or skin breakdown. In general, wounds are considered to be acute wounds if they are new. Wounds are considered to be chronic if they are more than 3-4 weeks old.
  • Wounds that can be treated using the methods and compositions described herein include open wounds and closed wounds, and occur on the skin surface, or just below the skin surface, or in mucous membranes. Wounds can also occur in internal organs due to surgery or trauma. Wounds also include ulcers, as described herein.
  • Open wounds are wounds where the skin surface is broken or penetrated. Open wounds include, for example:
  • Abrasions An abrasion occurs when skin rubs or scrapes against a rough or hard surface. Road rash is an example of an abrasion. Generally not a lot of bleeding.
  • Lacerations or incisions A laceration or incision is a deep cut or tearing of the skin.
  • Punctures A puncture is a small hole caused by a long, pointed object, such as a nail or needle. Sometimes, a bullet can cause a puncture wound. Punctures may not bleed much, but these wounds can be deep enough to damage internal organs.
  • Avulsions An avulsion is a partial or complete tearing away of skin and the tissue beneath. Avulsions usually occur during violent accidents, such as body-crushing accidents, explosions, and gunshots. They bleed heavily and rapidly.
  • Burns - includes thermal, chemical and electrical burns. As used herein“bums” explicitly excludes burns caused by exposure to sun (i.e., sun burns). Thus,“wounds” and“open wounds” also explicitly exclude sun burns.
  • “Closed wounds” are wounds where the skin surface is not broken or penetrated, and in general the wound occurs just below the skin surface. Closed wounds include, for example:
  • Blisters fluid filled pockets under the skin. Seroma: a fluid filled area that develops under the skin or body tissue (commonly occur after blunt trauma or surgery).
  • Hematoma a blood filled area that develops under the skin or body tissue (occur due to internal blood vessel damage to an artery or vein).
  • Crush injuries can be caused by extreme forces, or lesser forces over a long period of time.
  • Ulcers are lesions that wear down the skin or mucous membrane that can have various causes depending on their location. Ulcers are a gradual disturbance of tissues by an internal cause that originate from an impaired immune system or nervous system. Cells require blood, oxygen, and nutrients and anything that reduces the supply of these requirements can lead to ulcer formation. The most common types of internally originating skin ulcers are diabetic foot ulcers, venous leg ulcers, and pressure ulcers.
  • Skin ulcer types o Pressure ulcer: injury that causes breakdown of the skin and often the underlying tissue as well. Pressure ulcers can range in severity from discolored skin areas to large open wounds that expose the underlying bone or muscle.
  • DFU Diabetic Foot Ulcer
  • o Ulcerative dermatitis an ulcer due to a dermatological condition
  • o Genital ulcer painful, non-sexually acquired genital ulceration.
  • the methods described herein suitably“treat” a wound, which means that the methods and compositions result in the closure or healing of a wound.
  • methods for treating a wound comprise administering a composition comprising a therapeutically effective amount of nicotinamide riboside and a therapeutically effective amount of pterostilbene to a patient having the wound.
  • the methods suitably include administering orally the composition to the patient having the wound.
  • Oral administration can include providing a capsule, tablet, lozenge, syrup, liquid, etc., to a patient via the mouth. Additional methods and forms of oral administration are described throughout.
  • the methods include administering topically the composition to the patient having the wound.
  • Topical administration includes the application of a liquid, cream, foam, gel, salve, or other topical form as described herein, directly to the surface of the skin of the patient having the wound.
  • the topical application is made directly to the wound itself, as well as surrounding tissue to aid in healing of the wound.
  • the nicotinamide riboside and pterostilbene for use in the methods described herein are contained within the same formulation, suitably an oral formulation, including a liquid, drops, a spray, a solution, a gel, a powder, a suspension, or in a solid dosage form such as a lozenge, a capsule, a tablet, a pill, a gel-cap, a buccal or sub-lingual strip, etc.
  • the compositions contain nicotinamide riboside, a precursor of coenzyme NAD + , which is involved in metabolic processes such as energy production, DNA repair, cellular detoxification, the inflammatory response, and protein folding.
  • nicotinamide riboside a precursor of coenzyme NAD + , which is involved in metabolic processes such as energy production, DNA repair, cellular detoxification, the inflammatory response, and protein folding.
  • the chemical structure of nicotinamide riboside is provided below.
  • Nicotinamide riboside has four asymmetric centers and that any optical isomer, as separated, pure or partially purified optical isomers and any mixtures thereof including racemic mixtures can be used.
  • the enantiomeric form can be in enantiomeric excess, e.g., essentially in a pure form. Accordingly, some embodiments relate to nicotinamide riboside having an enantiomeric excess of at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 96%, at least 98%, and ranges therebetween.
  • Nicotinamide riboside is a quaternary salt and forms an ionic bond with a counteranion.
  • counteranions include the anions of suitable organic acid such as formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, itaconic, lactic, methanesulfonic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methane sulfonic, ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, p-toluenes
  • nicotinamide riboside may be substituted or combined with nicotinamide mononucleotide, niacinamide, nicotinamide, nicotinic acid, and/or niacin.
  • compositions also include pterostilbene.
  • Pterostilbene is a polyphenol based derivative of resveratrol and, like the NAD + precursor, promotes metabolic health.
  • the chemical structure of pterostilbene is provided below:
  • a derivative, salt, solvate, or prodrug of pterostilbene can be used in the compositions described herein.
  • pterostilbene may be substituted and/or combined with epsilon-viniferin and/or resveratrol.
  • compositions for use in the treatment methods are suitably formulated for oral delivery, i.e., in an oral formulation.
  • Oral solid dosage forms are described generally in Remington’s Pharmaceutical Sciences, 18thEd.l990 (Mack Publishing Co. Easton Pa.18042) at Chapter 89.
  • Solid dosage forms include tablets, capsules, pills, troches or lozenges, cachets, pellets, powders, or granules or incorporation of the material into particulate preparations of polymeric compounds such as polylactic acid, polyglycolic acid, etc., or into liposomes.
  • Such compositions may influence the physical state, stability, rate of in vivo release, and rate of in vivo clearance of the disclosed.
  • compositions may be prepared in liquid form, or may be in dried powder (e.g., lyophilized) form.
  • Liposomal or proteinoid encapsulation may be used to formulate the compositions. Liposomal encapsulation may be used and the liposomes may be derivatized with various polymers (e.g., U.S. Patent No.5, 013, 556). See also, Marshall, K. In: Modem Pharmaceutics Edited by G. S. Banker and C. T. Rhodes Chapter 10, 1979.
  • the formulation may include a peptide (or chemically modified forms thereof) and inert ingredients which protect compounds in the stomach environment, and release of the biologically active material in the intestine.
  • Nicotinamide riboside, niacinamide, nicotinamide, nicotinic acid, pterostilbene, nicotinamide mononucleotide, niacin, epsilon-viniferin, resveratrol or derivatives thereof may be chemically modified so that oral delivery of the compound is efficacious.
  • Contemplated chemical modification is the attachment of at least one moiety to the component molecule itself, where the moiety permits uptake into the blood stream from the stomach or intestine, or uptake directly into the intestinal mucosa.
  • the increase in overall stability of the component or components and increase in circulation time in the body Certain embodiments may be pharmaceutical compositions. Certain embodiments may be nutritional supplements.
  • Certain embodiments provide liquid dosage forms for oral administration, including pharmaceutically acceptable emulsions, solutions, suspensions, and syrups, which may contain other components including inert diluents, adjuvants such as wetting agents, emulsifying and suspending agents, and sweetening, and flavoring agents.
  • the methods can involve the use of a composition which is administered as a liquid with an active agent (i.e., nicotinamide riboside and/or pterostilbene) dissolved (e.g., solution) or dispersed (e.g., suspension) in the composition.
  • an active agent i.e., nicotinamide riboside and/or pterostilbene
  • the solution or suspension may be prepared using one or more pharmaceutically acceptable excipients.
  • Suitable excipients include, but are not limited to, surfactants, humectants, plasticizers, crystallization inhibitors, wetting agents, bulk filling agents, solubilizers, bioavailability enhancers, pH adjusting agents, flavorants and combinations
  • Controlled release oral formulations may be provided.
  • Controlled release may include, but is not limited to, delayed release and pH-dependent release.
  • the nicotinamide riboside and pterostilbene, or derivatives thereof can be incorporated into microcapsules, microparticulates, nanoparticulates, etc. through use of coatings to affect release of the active principle.
  • nicotinamide riboside and pterostilbene, or derivatives thereof can be incorporated into an inert matrix which permits release by either diffusion or leaching mechanisms, e.g., gums. Slowly degenerating matrices may also be incorporated into the formulation.
  • Modified release oral formulations may be provided. Modified release may allow for specific release profiles.
  • Extended release oral formulations may be provided. Extended release may allow for release of active ingredient over a desired time period.
  • controlled, modified or extended release oral formulation is a tablet, capsule, or microbeads for oral administration.
  • controlled, modified or extended release formulations comprising suitable and effective treatment amounts of the desired components may be pills, powders, granules, sterile parenteral solutions or suspensions, oral solutions or suspensions, oil-water emulsions as well as implants and microencapsulated delivery systems.
  • compositions of the present invention may comprise conventional pharmaceutical binders, excipients and additives, which may act to control, modify or extend release when used in sufficient quantities.
  • Coating agents e.g., plasticizers, may be used to enhance the controlled, modified or extended release features of the compositions of the invention.
  • the location of release may be the stomach, the small intestine (the duodenum, the jejunum, or the ileum), or the large intestine.
  • the release can avoid the deleterious effects of the stomach environment, either by protection of the agent (or derivative) or by release of the agent (or derivative) beyond the stomach environment, such as in the intestine.
  • a coating temporally impermeable to at least pH 5.0 is useful.
  • Examples of the more common inert ingredients that are used as enteric coatings are cellulose acetate trimellitate (CAT), hydroxypropylmethylcellulose phthalate (HPMCP), polyvinyl acetate phthalate (PVAP), poly(methacrylic acid-co-ethyl acrylate) 1 :1, cellulose acetate phthalate (CAP), poly(methacylic acid-co-methyl methacrylate) 1 : 1, poly(methacylic acid-co-methyl methacrylate) 1 :2, and natural shellac resin. These coatings may be used as mixed films.
  • the methods described herein utilize the oral administration of soft capsules containing nicotinamide riboside and pterostilbene or their equivalents.
  • the soft capsule can be prepared using techniques well known in the art. For example, soft capsules are typically produced using a rotary die encapsulation process. Active agent formulations are fed into the encapsulation machine by gravity.
  • the formulation comprises pharmaceutical excipients such as olive oil, gelatin, glycerin, purified water, beeswax yellow, sunflower lecithin, silicon dioxide, titanium dioxide, F. D. & C Blue 1 and F. D. & C Red 4, microcrystalline cellulose, hypromellose, vegetable magnesium stearate, and/or silica.
  • a capsule shell can comprise one or more plasticizers such as glycerin, sorbitol, sorbitans, maltitol, glycerol, polyethylene glycol, polyalcohols with 3 to 6 carbon atoms, citric acid, citric acid esters, triethyl citrate and combinations thereof.
  • the plasticizer is glycerin.
  • the capsule shell can include other suitable shell additives such as opacifiers, colorants, humectants, preservatives, flavorings, and buffering salts and acids.
  • suitable shell additives such as opacifiers, colorants, humectants, preservatives, flavorings, and buffering salts and acids.
  • Opacifiers are used to opacify the capsule shell when the encapsulated active agents are light sensitive. Suitable opacifiers include, but not limited to, titanium dioxide, zinc oxide, calcium carbonate and combinations thereof. In an embodiment, the opacifier is titanium dioxide.
  • Colorants can be used to for marketing and product identification and/or differentiation purposes. Suitable colorants include synthetic and natural dyes and combinations thereof.
  • Humectants can be used to suppress the water activity of the softgel.
  • Suitable humectants include glycerin and sorbitol, which are often components of the plasticizer composition. Due to the low water activity of dried, properly stored softgels, the greatest risk from microorganisms comes from molds and yeasts. For this reason, preservatives can be incorporated into the capsule shell. Suitable preservatives include alkyl esters of p-hydroxy benzoic acid such as methyl, ethyl, propyl, butyl and heptyl (collectively known as“parabens”) or combinations thereof.
  • compositions for use in the methods of treatment described herein are referred to as “BASIS®” and includes nicotinamide ribose (250 mg) and pterostilbene (50 mg) as the active ingredients.
  • This can be in a capsule formed of microcrystalline cellulose, hypromellose, vegetable magnesium stearate, olive oil, gelatin, glycerin, purified water, beeswax yellow, sunflower lecithin, silicon dioxide, titanium dioxide, F. D. & C Blue 1 and F. D. & C Red 4, or vegetarian hard capsules made solely of plant materials. Any embodiment may include microcrystalline cellulose, hypromellose, vegetable magnesium stearate, and/or silica.
  • compositions include acetyl-L- carnitine, N-acetyl cysteine, a-lipoic acid, biotin, vitamin B6, vitamin B12, folic acid, resveratrol, vinpocetine, chromium picolinate, vitamin D3, naringin, quercetin, and creatine.
  • the nicotinamide riboside and pterostilbene for use in the methods described herein are contained within the same formulation, suitably a topical formulation.
  • topical formulation refers to any form of a composition or formulation that can be applied to the surface of the skin, including the scalp, face, eyebrows, eyelashes, back, neck, trunk, legs, etc. Topical formulations include liquids, foams, powders, emulsions, sprays, creams, lotions, serums, salves, balms, etc.
  • components that can be included in topical formulations in addition to the nicotinamide riboside and pterostilbene include various moisturizers, humectants, odor modifiers, buffers, pigments, preservatives, Vitamins such as A, C and E, emulsifiers, dispersing agents, wetting agents, odor-modifying agents, gelling agents, stabilizers, propellants, antimicrobial agents, sunscreens, enzymes and the like.
  • the methods described herein comprise administering a therapeutically effective amount of nicotinamide riboside and a therapeutically effective amount of pterostilbene to a patient having the wound.
  • therapeutically effective refers to the amount of nicotinamide riboside and/or pterostilbene needed to produce close or heal a wound.
  • nicotinamide mononucleotide, niacinamide, nicotinamide, nicotinic acid and/or niacin may be substituted for nicotinamide riboside.
  • a combination of nicotinamide riboside, nicotinamide mononucleotide, and/or niacin may be used.
  • epsilon-viniferin and/or resveratrol may be substituted for pterostilbene.
  • a combination of pterostilbene, epsilon- viniferin, and/or resveratrol maybe used.
  • nicotinamide riboside or its equivalents is administered to a patient (either via a single composition, or in multiple, separate compositions) in an amount of between about 50 mg and about 1500 mg, between about 100 mg and about 1500 mg, between about 100 mg and about 1000 mg, between about 125 mg and about 900 mg, between about 150 mg and about 850 mg, between about 200 mg to 700 mg, between about 200 mg to about 500 mg, between about 1000 mg and about 1500 mg, or about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, about 500 mg, about 550 mg, about 600 mg, about 650 mg or about 700 mg nicotinamide.
  • these amounts are administered to a patient on a daily basis in the form of a single composition or multiple compositions.
  • the administration of nicotinamide riboside can be orally or topically,
  • pterostilbene or its equivalents is administered to a patient (either via a single composition or in multiple, separate compositions) in an amount between about 25 mg and about 1000 mg, between about 100 mg and about 1000 mg, between about 25 mg and about 500 mg per day, between about 25 mg and about 200 mg, between about 25 mg and about 250 mg, between about 30 mg and about 225 mg, between about 40 mg and about 200 mg, between about 45 mg and about 250 mg, or about 25 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, or about 150 mg pterostilbene.
  • these amounts are administered to a patient on a daily basis in the form of a single composition or multiple compositions.
  • the administration of pterostilbene can be orally or topically, as described herein.
  • the compounds, compositions or pharmaceutical compositions are prepared as oral formulations containing nicotinamide riboside and pterostilbene in the same composition.
  • the compounds, compositions or pharmaceutical compositions are prepared as topical formulations containing nicotinamide riboside and pterostilbene in the same composition.
  • the compounds, compositions or pharmaceutical compositions are prepared as oral formulations containing nicotinamide riboside and pterostilbene in different compositions, including different oral delivery types or formulations.
  • the compounds, compositions or pharmaceutical compositions are prepared as topical formulations containing nicotinamide riboside and pterostilbene in different compositions, including different topical delivery types or formulations.
  • the methods of treatment include administering a composition comprising a combination of nicotinamide riboside at about 200 mg to about 700 mg and pterostilbene at about 25 mg to about 200 mg to the patient, including a composition comprising amount 500 mg of nicotinamide riboside and about 100 mg pterostilbene.
  • the methods of treatment include administering a composition including a combination of nicotinamide riboside at about 250 mg and pterostilbene at about 50 mg to the patient.
  • the methods of treatment include administering two or more doses of such as composition, such that a total of about 500 mg nicotinamide riboside and about 100 mg pterostilbene is administered to the patient on a daily basis.
  • the administration of the composition can be orally or topically, as described herein.
  • a composition may be administered in a dosage regimen over days, weeks, or months. Dosages may be multiple times per day or singular doses per day. Each dosage when dosages are administered over multiple days, weeks, or months may not be equal amounts. Dosage amounts during a dosage regimen may vary according to the amounts and ranges disclosed herein.
  • the compositions described herein are administered on a daily basis for a period of at least 4 weeks, suitably for a period of at least 1 month, or for a period of at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, etc.
  • the compositions described herein can also be administered to a patient for 1 or more years, including for the lifetime of a patient. Dosage can be provided orally or topically, as described herein.
  • methods are provided herein for treating an open wound, comprising administering a composition consisting essentially of a therapeutically effective amount of nicotinamide riboside and a therapeutically effective amount of pterostilbene to a patient having the open wound.
  • methods are provided herein for treating an closed wound, comprising administering a composition consisting essentially of a therapeutically effective amount of nicotinamide riboside and a therapeutically effective amount of pterostilbene to a patient having the open wound.
  • compositions and formulations that“consist essentially” of the recited ingredients contain the recited components and those that do not materially affect the basic and novel characteristics of the claimed formulations.
  • Components that do not materially affect the basic and novel characteristics of the claimed formulations are those that do not limit the ability of the nicotinamide riboside and pterostilbene to heal the wound.
  • compositions and formulations that consist essentially of the recited ingredients specifically exclude other active agents for treatment of the wound.
  • oral compositions and formulations that “consist essentially” of the recited ingredients, such oral compositions and formulations contain the recited components and those that do not materially affect the basic and novel characteristics of the claimed formulations.
  • Components that do not materially affect the basic and novel characteristics of the claimed oral formulations are those that do not limit the ability of the nicotinamide riboside and pterostilbene to heal the wound, and include various oral excipients.
  • oral compositions and formulations that consist essentially of the recited ingredients specifically exclude other active agents for treatment of the wound.
  • topical compositions and formulations that“consist essentially” of the recited ingredients contain the recited components and those that do not materially affect the basic and novel characteristics of the claimed formulations.
  • Components that do not materially affect the basic and novel characteristics of the claimed topical formulations are those that do not limit the ability of the nicotinamide riboside and pterostilbene to heal the wound, and include various topical excipients.
  • topical compositions and formulations that consist essentially of the recited ingredients specifically exclude other active agents for treatment of the wound.
  • the methods of treatment described herein can be utilized in combination with well-known wound dressings and bandages. While other compounds can be provided in addition the nicotinamide riboside and pterostilbene formulations described herein, suitably no other compounds are provided to the patient to aid in the wound healing.
  • the methods described herein result in a healing rate of the wound that is at least 10% faster than without the administration of the compositions and formulations described herein.
  • a“healing rate” refers to the time needed for wound closure or the time needed for the skin to return to an unwounded state.
  • Healing rate can be measured using any well-known method including for example, measurements of wound area, wound perimeter, or mutually perpendicular diameters (largest diameter of the wound, and diameter taken at right angle to largest diameter), with respect to time.
  • healing rate refers to the advance of the wound margin towards the wound center, measured with respect to time (i.e., per day), which allows for comparison of wounds with different initial areas.
  • the healing rate of a wound (suitably measured in days until the wound is healed) with the administration of the compositions and formulations described herein (i.e., treated) is compared to the healing rate of a wound without the administration (i.e., control), and the difference in rate (i.e., length of time in days) is compared to the control rate to determine the increase in healing rate.
  • compositions and methods described herein can also be compared to other compounds or wound dressings acting as controls to measure an increase in healing rate of the present compounds in comparison to other methods and formulations.
  • the methods described herein i.e., treated
  • the administration described herein results in an increase in an immune response of the patient as a result of the combination of nicotinamide riboside and pterostilbene. This immune response can happen more quickly, or provide more neutrophils, and monocytemacrophages to the wound site.
  • Embodiment 1 is a method for treating a wound, comprising administering a composition comprising a therapeutically effective amount of nicotinamide riboside and a therapeutically effective amount of pterostilbene to a patient having the wound.
  • Embodiment 2 includes the method of embodiment 1, comprising administering orally the composition to the patient having the wound.
  • Embodiment 3 includes the method of embodiment 1, comprising administering topically the composition to the patient having the wound.
  • Embodiment 4 includes the method of any of embodiments 1-3, wherein the composition comprises a combination of nicotinamide riboside at about 200 mg to about 700 mg and pterostilbene at about 25 mg to about 200 mg.
  • Embodiment 5 includes the method of any of embodiments 1-4, wherein the composition comprises a combination of nicotinamide riboside at about 250 mg and pterostilbene at about 50 mg.
  • Embodiment 6 includes the method of any of embodiments 1-5, wherein the wound is an open wound, a closed wound, or an ulcer.
  • Embodiment 7 includes the method of embodiment 6, wherein the open wound is selected from the group consisting of a laceration, an incision, a puncture, an avulsion or an abrasion.
  • Embodiment 8 includes the method of embodiment 6, wherein the closed wound is selected from the group consisting of a contusion, a blister, a seroma and a hematoma.
  • Embodiment 9 is a method for treating an open wound, comprising administering a composition consisting essentially of a therapeutically effective amount of nicotinamide riboside and a therapeutically effective amount of pterostilbene to a patient having the open wound.
  • Embodiment 10 includes the method of embodiment 9, comprising administering orally the composition to the patient having the wound.
  • Embodiment 11 includes the method of embodiment 9, comprising administering topically the composition to the patient having the wound.
  • Embodiment 12 includes the method of any of embodiments 9-11, wherein the composition consists essentially of a combination of nicotinamide riboside at about 200 mg to about 700 mg and pterostilbene at about 25 mg to about 200 mg.
  • Embodiment 13 includes the method of any of embodiments 9-12, wherein the composition consists essentially of a combination of nicotinamide riboside at about 250 mg and pterostilbene at about 50 mg.
  • Embodiment 14 includes the method of any of embodiments 9-13, wherein the open wound is selected from the group consisting of a laceration, an incision, a puncture, an avulsion or an abrasion.
  • Embodiment 15 is a method for treating a closed wound, comprising administering a composition consisting essentially of a therapeutically effective amount of nicotinamide riboside and a therapeutically effective amount of pterostilbene to a patient having the closed wound.
  • Embodiment 16 includes the method of embodiment 15, comprising administering orally the composition to the patient having the wound.
  • Embodiment 17 includes the method of embodiment 15, comprising administering topically the composition to the patient having the wound.
  • Embodiment 18 includes the method of any of embodiments 15-17, wherein the composition consists essentially of a combination of nicotinamide riboside at about 200 mg to about 700 mg and pterostilbene at about 25 mg to about 200 mg.
  • Embodiment 19 includes the method of any of embodiments 15-17, wherein the composition consists essentially of a combination of nicotinamide riboside at about 250 mg and pterostilbene at about 50 mg.
  • Embodiment 20 includes the method of any of embodiments 15-19, wherein the closed wound is selected from the group consisting of a contusion, a blister, a seroma and a hematoma.
  • Embodiment 21 includes the method of any of embodiments 1-20, wherein the administration results in a healing rate of the wound that is at least 20% faster than without the administration.
  • Embodiment 22 includes the method of embodiment 21, wherein the healing rate of the wound is at least 40% faster than without the administration.
  • Example 1 Prevention of Ear-induced swelling using nicotinamide riboside and pterostilbene
  • UVB ultraviolet B radiation
  • Group 2 SD supplemented with 0.04% PT
  • Group 3 SD, plus water containing 0.2% NR
  • Group 4 SD supplemented with 0.04% PT, plus water containing 0.2% NR
  • mice were fed their respective diets for four weeks prior to UVB exposure. The thickness of the ear was measured prior to UVB exposure (using a spring-loaded micrometer), and then the mice were placed in individual compartments and their ears exposed once to 3,500 J/m 2 UVB. Ear thickness was subsequently measured at 24-, 48- and 96-hours post-exposure. A separate cohort of mice were euthanized 24-hours post-exposure in order to harvest back skin for evaluation of 6,4 pyrimidine-pyrimidone (6,4 PPD) photo-product formation.
  • 6,4 PPD 6,4 pyrimidine-pyrimidone
  • 6,4 PPD is a marker of DNA damage.
  • mice treated with either PT or NR+PT BASIS
  • a significant reduction P ⁇ 0.01 for both PT and NR+PT-treated animals was observed (FIG. 2), indicating a reduction in DNA damage.
  • Example 2 In vitro Scratch Test to Measure the Effect of Nicotinamide Riboside and Pterostilbene on Cell Migration.
  • a in vitro scratch test is utilized to examine the effect of nicotinamide riboside (NR) and pterostilbene (PT), separately and in combination, to determine the effect on cell migration as a measure of wound healing.
  • NR nicotinamide riboside
  • PT pterostilbene
  • the scratch test is carried out as described in Liang et al .,“ In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro ,” Nature Protocols 2: 329-333 (2007) (the disclosure of which is incorporated by reference herein in its entirety, particularly for the methods of carrying out the scratch test).
  • the test involves creating a “scratch” in a cell monolayer, capturing images of the cells at the beginning and at regular intervals during cell migration to close the scratch, and comparing the images to quantify the migration rate of the cells.
  • the in vitro scratch assay is suitable for studies on the effects of cell-matrix and cell-cell interactions on cell migration, and mimics cell migration during wound healing in vivo, and are compatible with imaging of live cells during migration.
  • Exemplary cells that can be used in the assays include fibroblasts, epithelial cells and endothelial cells.
  • a scratch is generated in a cell monolayer.
  • a green fluorescent protein can be transfected into the cells to follow a desired gene or protein during the healing process, as described in Liang et al.
  • Nicotinamide riboside (NR) and pterostilbene (PT), separately and in combination, are then added to different cell culture plates, along with appropriate controls examining vehicle only (e.g., buffer, etc.).
  • vehicle only e.g., buffer, etc.
  • the amounts of NR and PT are scaled appropriately to maintain a desired ratio of the two compounds to examine their effects, and can be increased or decreased by varying amounts (e.g. 0.1-100 times), to examine various ranges.
  • Example 3 Increase in wound healing rate with nicotinamide riboside and pterostilbene in mouse wound healing model
  • Group 1 Standard diet (SD)
  • Group 2 SD supplemented with 0.04% PT
  • Group 3 SD, plus water containing 0.2% NR
  • Group 4 SD supplemented with 0.04% PT, plus water containing 0.2% NR
  • a mouse excisional wound is created in accordance with Wang et al .,“The mouse excisional wound splinting model, including applications for stem cell transplantation,” Nature Protocols 5:302-309 (2013) (the disclosure of which is incorporated by reference herein in its entirety, particularly for the methods described therein related to generation of the wound in the mouse model).
  • the mouse excisional wound splinting model utilizes a splinting ring tightly adhered to the skin around the wound, preventing local skin contraction. The wound therefore heals through granulation and re-epithelialization, a process similar to that occurring in humans. The model, takes 2-4 weeks to carry out.
  • wound area, perimeter and distance of wound margin relative the wound center are measured daily for a period of 15-30 days during the healing process to determine the effect of PT, NR and the combination of PT and NR.
  • 0.04% PT and 0.2% NR are administered individually and in combination in order to explore whether the ingredients act synergistically to increase the wound healing rate.
  • the combination of 0.04% PT and 0.2% NR is expected to statistically increase the wound healing rate relative to controls.
  • Example 4 Increase in wound healing rate with nicotinamide riboside and pterostilbene in human wound healing models
  • Tape stripping - involving removal of the stratum comeum with adhesive tape. Generally leaving the epidermal compartment in tact. Healing can be measured by examining the change in transepidermal water loss as a function of time, as a measure of the change in skin permeability. Re-epithelization can also be measured as a determination of the wound healing rate.
  • Abrasive wound model generally involving the infliction of standardized, superficial abrasions by repeatedly abrading the skin with a surgical brush until the first signs of uniform glistening and punctuate bleeding are observed. Wound healing can then be observed, generally without scarring.
  • Laser wound model - can be initiated using CO2 or Er:YAG lasers to create wounds of various depths, suitably with a surface area of a few square centimeters. In general, part of the epidermis is removed.
  • Microdermabrasion generally involving the use of a spray of microcrystals or a diamond abrasive surface to remove part of the epidermis.
  • Biopsy - utilizes a fill thickness wound, including the removal of epidermis and dermis, often with a punch or scalpel/
  • a patient or patient group is provided with oral or topical Notinamide riboside (NR), and pterostilbene (PT), or both NR and PT, in a suitable oral or topical formulation.
  • NR Notinamide riboside
  • PT pterostilbene
  • Amounts of NR and PT are described herein, as are suitably formulation forms. Control groups utilizing only oral or topical carriers or excipients are also utilized.
  • nicotinamide riboside is administered (orally or topically) at about 250 mg to one patient group; pterostilbene at about 50 mg to one patient group; and another patient group receives a combination of NR at 250 mg and PT at 50 mg, for example orally as BASIS.
  • the wound is followed for a period of 7 days to 4 weeks or more, with wound measurements made on a weekly basis or twice per week, observing the closure or healing of the wound to calculate a wound healing rate.
  • NR and PT results in an increased wound healing rate compared to either compound alone, or in comparison to controls without active agents, suitably with an increase in healing rate that is suitably at least 20% faster.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des méthodes pour le traitement de plaies par l'administration d'une association de nicotinamide riboside et de ptérostilbène. Les compositions peuvent être administrées par voie orale ou en tant que formulation topique.
PCT/US2020/022596 2019-03-21 2020-03-13 Méthodes pour le traitement de plaies Ceased WO2020190703A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962821779P 2019-03-21 2019-03-21
US62/821,779 2019-03-21

Publications (1)

Publication Number Publication Date
WO2020190703A1 true WO2020190703A1 (fr) 2020-09-24

Family

ID=72520474

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/022596 Ceased WO2020190703A1 (fr) 2019-03-21 2020-03-13 Méthodes pour le traitement de plaies

Country Status (1)

Country Link
WO (1) WO2020190703A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160272668A1 (en) * 2015-03-16 2016-09-22 ChromaDex Inc. Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof to enhance skin permeation in treating skin conditions
US20180353497A1 (en) * 2015-06-10 2018-12-13 Elysium Health, Inc. Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders
WO2018236814A2 (fr) * 2017-06-19 2018-12-27 Gangadhara Ganapati Dérivés de nicotinamide riboside et leurs utilisations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160272668A1 (en) * 2015-03-16 2016-09-22 ChromaDex Inc. Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof to enhance skin permeation in treating skin conditions
US20180353497A1 (en) * 2015-06-10 2018-12-13 Elysium Health, Inc. Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders
WO2018236814A2 (fr) * 2017-06-19 2018-12-27 Gangadhara Ganapati Dérivés de nicotinamide riboside et leurs utilisations

Similar Documents

Publication Publication Date Title
DE69529345T2 (de) Wundheilendes sonnenschutzmittel
AU2018255294B2 (en) Parenteral non-systemic administration of buffering agents for inhibiting metastasis of solid tumors, hyperpigmentation and gout
FR2768927A1 (fr) Utilisation de l'acide ellagique, de ses sels, de ses complexes metalliques, de ses derives mono- ou poly-ethers, mono- ou poly-acyles dans le domaine de la cosmetique et de la pharmacie, notamment de la dermatologie
JP2003526622A (ja) 老化防御効果を示すテトラペプチド、これを基にした薬理学的物質、及びその利用法
RU2336870C2 (ru) Применение l-бутилфталида для изготовления лекарственного средства для профилактики и лечения церебрального инфаркта
JP5891651B2 (ja) 角層細胞分化正常化用皮膚外用剤
CN101384246B (zh) 含二氢黄酮衍生物的皮肤外用制剂
JP2019006696A (ja) 活性酸素消去剤
DE60212143T2 (de) Verwendung von thrombin-peptidderivaten zur behandlung von chronischen hautulcera
CN114209683A (zh) 壬二酸在制备治疗炎症性肠病药物中的应用
KR20200112012A (ko) (R)-진세노사이드 Rg3를 유효성분으로 포함하는 피부상처 치유 또는 피부재생 촉진용 조성물
CN113056268A (zh) 纤溶酶原激活物抑制剂1(pai-1)抑制剂和其用途
US8158138B1 (en) Urea compositions and their methods of manufacture
WO2020190703A1 (fr) Méthodes pour le traitement de plaies
JP7361448B2 (ja) トランスグルタミナーゼ発現促進剤
JPWO2007011066A1 (ja) 繊維芽細胞賦活剤、コラーゲン産生促進剤、コラーゲン収縮促進剤、ヒアルロン酸産生促進剤、ａｔｐ産生促進剤、メラニン生成抑制剤、皮膚外用剤
JP6656890B2 (ja) フィラグリン産生促進剤
JP5033381B2 (ja) 外用医薬組成物
CN116782910A (zh) 屏障功能改善剂
JP2000256196A (ja) 抗炎症，抗アレルギー剤
CN115845026A (zh) 乙酰基二肽-1鲸蜡酯及其组合物与用途
JP5460766B2 (ja) 外用医薬組成物
JP2004519413A (ja) 局所微量栄養素送達システムおよびその用途
JP2017088558A (ja) セラミド合成促進剤
JPH06192082A (ja) 細胞膜老化改善剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20773088

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20773088

Country of ref document: EP

Kind code of ref document: A1